NO20050689L - Terapeutisk anvendelse - Google Patents

Terapeutisk anvendelse

Info

Publication number
NO20050689L
NO20050689L NO20050689A NO20050689A NO20050689L NO 20050689 L NO20050689 L NO 20050689L NO 20050689 A NO20050689 A NO 20050689A NO 20050689 A NO20050689 A NO 20050689A NO 20050689 L NO20050689 L NO 20050689L
Authority
NO
Norway
Prior art keywords
therapeutic use
therapeutic
Prior art date
Application number
NO20050689A
Other languages
English (en)
Other versions
NO330756B1 (no
Inventor
Francis Thomas Boyle
Marianne Ashford
David William Tonge
Sian Tomiko Taylor
Andrew Mark Hughes
Donna Johnstone
Nigel Charles Barrass
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9942847&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20050689(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of NO20050689L publication Critical patent/NO20050689L/no
Publication of NO330756B1 publication Critical patent/NO330756B1/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P23/00—Anaesthetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
NO20050689A 2002-08-23 2005-02-09 N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft NO330756B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0219660.8A GB0219660D0 (en) 2002-08-23 2002-08-23 Therapeutic use
PCT/GB2003/003653 WO2004018044A2 (en) 2002-08-23 2003-08-20 N-(3-methoxy-5-methylpyrazin-2-yl)-2-(4-'1,3,4-oxadiazol-2-yl!phenyl)pyridine-3 sulphonamide as an anticancer agent

Publications (2)

Publication Number Publication Date
NO20050689L true NO20050689L (no) 2005-03-21
NO330756B1 NO330756B1 (no) 2011-07-04

Family

ID=9942847

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050689A NO330756B1 (no) 2002-08-23 2005-02-09 N-(3-metoksy-5-metylpyrazin-2-yl)-2-(4-[1,3,4-oksadiazol-2-yl]fenyl)pyridin-3-sulfonamid, eller et farmasoytisk akseptabelt salt av denne, til behandling av kreft

Country Status (32)

Country Link
US (2) US7820679B2 (no)
EP (2) EP1545710B1 (no)
JP (2) JP3663202B2 (no)
KR (1) KR20050035280A (no)
CN (1) CN100467023C (no)
AR (1) AR041037A1 (no)
AT (1) ATE427773T1 (no)
AU (1) AU2003255835B8 (no)
BR (1) BR0313655A (no)
CA (1) CA2496476C (no)
CL (1) CL2003001692A1 (no)
CY (1) CY1110712T1 (no)
DE (1) DE60327084D1 (no)
DK (1) DK1545710T3 (no)
ES (1) ES2323309T3 (no)
GB (1) GB0219660D0 (no)
HK (1) HK1077534A1 (no)
IL (1) IL166730A0 (no)
IS (1) IS2704B (no)
MX (1) MXPA05001862A (no)
MY (2) MY137595A (no)
NO (1) NO330756B1 (no)
NZ (1) NZ538114A (no)
PL (1) PL375561A1 (no)
PT (1) PT1545710E (no)
RU (1) RU2340343C2 (no)
SA (1) SA03240363B1 (no)
SI (1) SI1545710T1 (no)
TW (1) TWI302912B (no)
UA (1) UA82071C2 (no)
WO (1) WO2004018044A2 (no)
ZA (1) ZA200501267B (no)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) * 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) * 2005-07-19 2005-08-24 Astrazeneca Ab Salt
WO2007111350A1 (ja) * 2006-03-28 2007-10-04 Osaka Bioscience Institute 血管新生ならびに癌細胞のmesenchymal型およびamoeboid型浸潤を阻害するための薬剤
WO2009024820A2 (en) * 2007-08-17 2009-02-26 Astrazeneca Ab Therapeutic treatment 014
AU2008309385B2 (en) * 2007-10-12 2011-10-20 Astrazeneca Ab Zibotentan composition containing mannitol and/or microcrystalline cellulose
WO2009068906A2 (en) * 2007-11-26 2009-06-04 Astrazeneca Ab Combinations comprising zd4054 and a src family kinase inhibitor 172
WO2010004337A1 (en) * 2008-07-10 2010-01-14 Astrazeneca Ab Combinations comprising n-(3-methoxy-5-methylpyrazin-2-yl)-2- (4-[1,3,4-oxadiazol-2-yl]phenyl)pyridine-3-sulphonamide and pemetrexed
RU2631487C2 (ru) * 2011-05-17 2017-09-22 Плексксикон Инк. Модуляция киназ и показания к её применению
CN102491973A (zh) * 2011-12-15 2012-06-13 南京友杰医药科技有限公司 Zd-4054的合成方法

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464853A (en) * 1993-05-20 1995-11-07 Immunopharmaceutics, Inc. N-(5-isoxazolyl)biphenylsulfonamides, N-(3-isoxazolyl)biphenylsulfonamides and derivatives thereof that modulate the activity of endothelin
US5591761A (en) 1993-05-20 1997-01-07 Texas Biotechnology Corporation Thiophenyl-, furyl-and pyrrolyl-sulfonamides and derivatives thereof that modulate the activity of endothelin
US5514691A (en) * 1993-05-20 1996-05-07 Immunopharmaceutics, Inc. N-(4-halo-isoxazolyl)-sulfonamides and derivatives thereof that modulate the activity of endothelin
TW270116B (no) 1991-04-25 1996-02-11 Hoffmann La Roche
RU2086544C1 (ru) 1991-06-13 1997-08-10 Хоффманн-Ля Рош АГ Бензолсульфонамидные производные пиримидина или их соли, фармацевтическая композиция для лечения заболеваний, связанных с активностью эндотелина
TW224462B (no) 1992-02-24 1994-06-01 Squibb & Sons Inc
NZ247440A (en) 1992-05-06 1995-04-27 Squibb & Sons Inc Phenyl sulphonamide derivatives, preparation and pharmaceutical compositions thereof
US5965732A (en) 1993-08-30 1999-10-12 Bristol-Myers Squibb Co. Sulfonamide endothelin antagonists
US6063911A (en) 1993-12-01 2000-05-16 Marine Polymer Technologies, Inc. Methods and compositions for treatment of cell proliferative disorders
GB9504854D0 (en) 1994-03-31 1995-04-26 Zeneca Ltd Nitrogen derivatives
GB9409618D0 (en) 1994-05-13 1994-07-06 Zeneca Ltd Pyridine derivatives
AU3642795A (en) 1994-09-27 1996-04-19 Merck & Co., Inc. Endothelin receptor antagonists for the treatment of emesis
GB2295616A (en) 1994-12-01 1996-06-05 Zeneca Ltd N-Diazine-benzenesulphonamide derivatives as endothelin receptor antagonists
UA58494C2 (uk) * 1995-06-07 2003-08-15 Зенека Лімітед Похідні n-гетероарилпіридинсульфонаміду, фармацевтична композиція, спосіб одержання та спосіб протидії впливам ендотеліну
GB9512697D0 (en) 1995-06-22 1995-08-23 Zeneca Ltd Heterocyclic compounds
US5780435A (en) * 1995-12-15 1998-07-14 Praecis Pharmaceuticals Incorporated Methods for treating prostate cancer with LHRH-R antagonists
GB9704762D0 (en) 1997-03-07 1997-04-23 Zeneca Ltd Chemical process
AU3011299A (en) 1998-03-23 1999-10-18 Merck & Co., Inc. Combination therapy for the treatment of benign prostatic hyperplasia
US6673832B1 (en) 1998-05-04 2004-01-06 Gudarz Davar Methods for identifying compounds for treating pain
DE69942009D1 (de) 1998-10-15 2010-03-25 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
US7566452B1 (en) 1999-05-04 2009-07-28 New York University Cancer treatment with endothelin receptor antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
DE60030764T2 (de) 1999-12-15 2007-09-13 Bristol-Myers Squibb Co. Biphenyl - sulfonamide als duale angiotensin - endothelin - rezeptor - antagonisten
US6774131B1 (en) 2000-02-16 2004-08-10 Yamanouchi Pharmaceutical Co., Ltd. Remedies for endothelin-induced diseases
AU2001264570A1 (en) 2000-05-31 2001-12-11 Warner Lambert Company Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
TWI306760B (en) 2000-08-07 2009-03-01 Abbott Lab Use of an endothelin et-a receptor antagonist and orally delivered pharmaceutical composition comprising the same
US20020055457A1 (en) * 2000-08-07 2002-05-09 Janus Todd J. Methods of treating cancer and the pain associated therewith using endothelin antagonists
DE10113366A1 (de) 2001-03-20 2002-09-26 Boehringer Ingelheim Pharma Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und Endothelinantagonisten
WO2002049630A2 (en) * 2000-12-21 2002-06-27 Bristol-Myers Squibb Company Method for preventing or treating pain by administering an endothelin antagonist
IL157734A0 (en) 2001-03-06 2004-03-28 Cellegy Pharma Inc Pharmaceutical compositions for the treatment of urogenital disorders
GB0108689D0 (en) 2001-04-05 2001-05-30 Medical Res Council Neuropathologies associated with expression of TNF-a
PE20021032A1 (es) 2001-04-11 2002-11-12 Abbott Lab Composicion farmaceutica para uso en la modulacion favorable de la calidad de vida relacionada con la salud y progresion temporal ajustada a la calidad relacionada con la salud de una enfermedad en pacientes con cancer de prostata
US20030092757A1 (en) * 2001-04-11 2003-05-15 Amitabh Singh Favorable modulation of health-related quality of life and health-related quality-adjusted time-to-progression of disease in patients with prostate cancer
WO2003006041A1 (fr) 2001-07-12 2003-01-23 Takeda Chemical Industries, Ltd. Agents prophylactiques/therapeutiques contre les tumeurs malignes
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
WO2003015820A1 (fr) 2001-08-10 2003-02-27 Takeda Chemical Industries, Ltd. Medicaments combines d'agoniste de la gnrh
DE10155076A1 (de) 2001-11-09 2003-05-22 Merck Patent Gmbh Verwendung von Endothelin-Rezeptor-Antagonisten zur Behandlung von Tumorerkrankungen
US7973064B2 (en) 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
GB0223367D0 (en) 2002-10-09 2002-11-13 Astrazeneca Ab Therapeutic treatment
GB0223854D0 (en) 2002-10-12 2002-11-20 Astrazeneca Ab Therapeutic treatment
GB0320806D0 (en) 2003-09-05 2003-10-08 Astrazeneca Ab Therapeutic treatment
BRPI0417838A (pt) 2003-12-20 2007-04-17 Merck Patent Gmbh derivados de tetrahidroquinolina substituìdos por 2-(hetero) arila
GB0403744D0 (en) 2004-02-20 2004-03-24 Astrazeneca Ab Chemical process
GB0425854D0 (en) 2004-11-25 2004-12-29 Astrazeneca Ab Therapeutic treatment
GB0514743D0 (en) 2005-07-19 2005-08-24 Astrazeneca Ab Salt

Also Published As

Publication number Publication date
KR20050035280A (ko) 2005-04-15
NO330756B1 (no) 2011-07-04
CA2496476C (en) 2009-08-04
AU2003255835A1 (en) 2004-03-11
CA2496476A1 (en) 2004-03-04
JP2004083590A (ja) 2004-03-18
DK1545710T3 (da) 2009-06-29
AU2003255835B2 (en) 2007-04-05
PL375561A1 (en) 2005-11-28
CL2003001692A1 (es) 2005-01-21
CY1110712T1 (el) 2015-06-10
EP1545710B1 (en) 2009-04-08
ES2323309T3 (es) 2009-07-13
AR041037A1 (es) 2005-04-27
RU2005108349A (ru) 2005-08-27
ATE427773T1 (de) 2009-04-15
JP2005097312A (ja) 2005-04-14
RU2340343C2 (ru) 2008-12-10
CN100467023C (zh) 2009-03-11
MXPA05001862A (es) 2005-06-03
CN1688365A (zh) 2005-10-26
HK1077534A1 (en) 2006-02-17
US7820679B2 (en) 2010-10-26
US20060094729A1 (en) 2006-05-04
WO2004018044A3 (en) 2004-05-06
EP2072082A2 (en) 2009-06-24
PT1545710E (pt) 2009-05-26
IS2704B (is) 2010-12-15
MY137595A (en) 2009-02-27
EP1545710A2 (en) 2005-06-29
IL166730A0 (en) 2006-01-15
JP3663202B2 (ja) 2005-06-22
US20110003831A1 (en) 2011-01-06
MY136449A (en) 2008-10-31
TWI302912B (en) 2008-11-11
WO2004018044A8 (en) 2004-06-24
UA82071C2 (en) 2008-03-11
BR0313655A (pt) 2005-06-21
NZ538114A (en) 2008-02-29
IS7766A (is) 2005-03-22
DE60327084D1 (de) 2009-05-20
SI1545710T1 (sl) 2009-08-31
AU2003255835B8 (en) 2007-05-17
GB0219660D0 (en) 2002-10-02
ZA200501267B (en) 2006-10-25
TW200409768A (en) 2004-06-16
WO2004018044A2 (en) 2004-03-04
EP2072082A3 (en) 2009-12-23
SA03240363B1 (ar) 2009-04-11

Similar Documents

Publication Publication Date Title
NO20052914D0 (no) Terapeutiske forbindelser
DE60336213D1 (de) Chirurgisches klammergerät
DE60324099D1 (de) Arzneistoffhaltiger tampon
DE50311558D1 (de) Inhalationstherapievorrichtung
NO20050689L (no) Terapeutisk anvendelse
IS7825A (is) Meðferðarfræðileg meðhöndlun
DK1597171T3 (da) Terapeutisk mikroskum
DE50303208D1 (de) Osteosyntheseeinrichtung
ITBO20020206A1 (it) Vasca idromassaggio
DE60328488D1 (de) Ng
NO20022747D0 (no) Behandlingsstol
FI20021817A0 (fi) Kanyyli
SE0200450D0 (sv) Therapeutic agents
SE0203826D0 (sv) Therapeutic agents
FI20020356A0 (fi) Sauna
SE0201783D0 (sv) Medical use
DE60333157D1 (de) Medizinisches Gerät
NO20043433L (no) Fremgangsmate
SE0203450D0 (sv) Therapeutic heterocycles
SE0203451D0 (sv) Therapeutic Heterocycles
UA7211S (uk) Масажер
UA7206S (uk) Масажер
SE0201152D0 (sv) New use
SE0202963D0 (sv) New use
SE0202837D0 (sv) New use

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees